|
The U.S. Food and Drug Administration approved Entereg (alvimopan) to accelerate the restoration of normal bowel function in patients 18 years and up who have undergone partial large or small bowel resection surgery. Entereg will be used in hospitalized patients who can receive no more than 15...
Under 10 mmHg CO2 pressure, there were no obvious effects on MKN-45 cells' proliferation and apoptosis. At 15 mmHg CO2 insufflation pressure, cells proliferation was inhibited and apoptosis improved. It may be that CO2 gas affected the growth of gastric cancer cells.This study was performed by a...
Biotech firm offers to reproduce dogs for 5 highest bidders BioArts International chief executive Lou Hawthorne poses with dogs cloned from his family pet on May 3, in Mill Valley, Calif. SAN FRANCISCO - Opening bids start at $100,000 for the service being offered by Mill Valley-based BioArts...
New research by the Gladstone Institutes of Cardiovascular Disease (GICD) and the University of California, San Francisco (UCSF), has revealed the genetic determinants of fat storage in cells, which may lead to a new understanding of and potential treatments for obesity, diabetes, and heart disease.
Researchers from Dendreon Corporation (Nasdaq: DNDN) presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), to treat benign prostatic hyperplasia (BPH).
SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the appointment of Dr.
Posted on: Thursday, 22 May 2008, 11:53 CDT Amgen (NASDAQ: AMGN) today posted to the company's Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The AmgenMED and Amgen Foundation grant and donation lists, as well as the guidelines...
Ardea Biosciences, Inc. today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment...
LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (NASDAQ: NEOL - News ) today announced that it has signed a letter of intent with SIRO ClinPharm USA (“SIRO”) with regard to SIRO’s engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox...
Donderdag 22 mei 2008 | Business Wire ] NEW YORK--(BUSINESS WIRE)--21 mei, 2008-- Smartanalyst, een pionier op het gebied van het leveren van wereldwijd strategisch onderzoek en analytische toepassingen aan de farmaceutische en biotechnologische sector, meldt de lancering van hun op oncologie...
